Conference Call with Shalby Ltd. Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Shalby announced Q3FY25 results Consolidated Revenue at Rs 2,811 million in Q3FY25. Consolidated EBITDA at Rs 393 million in Q3FY25. Consolidated PBT at Rs 124 million in Q3FY25. Occupied Bed during the quarter were 646. In patient count (incl. Day Care) of 22,369 growth of 7.9% YoY. ARPOB during the quarter was 42,704, growth of 14.4% YoY. Shanay Shah, President, Shalby, said: The company has shown a decent consolidated performance in Q3FY25 with a revenue of 281 crore with growth of 27.4% on YoY basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year. I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 7.9% rise in In-patient count (including day care) year-on-year in Q3FY25. Notably, ARPOB and ALOS stood at Rs 42,704 and 3.62 respectively in Q3FY25, compared to Rs 37,342 and 3.79 in the corresponding quarter of the previous year improved by 14.4% and 4.5% respectively. Our core specialties, including Arthroplasty, Onco-Science, Cardiac Science, Orthopaedic, Critical Care & General Medicine, and Neurology, collectively contributed 80% to the revenues in Q3FY25. On a standalone performance, our revenue has grown by 13.3% to Rs 227 crore and EBITDA has grown marginally by 0.8% to Rs 48.8 crore with the EBITDA margin of 21.5% on YoY basis. Our Homecare business contributed Rs 3.6 crore in Q3FY25 compared to Rs 3.4 crore in Q3FY24. Additionally, our Shalby Academy vertical witnessed an encouraging response, with over 1000 students enrolled in various healthcare programs during Q3FY25. Furthermore, our Realized Return on Capital Employed from the hospital business stood at 15% in Q3’FY25 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 2,667 million, with a net cash balance of Rs 660 million at the standalone level, reinforcing our ability to support strategic growth initiatives. In January’25 Shalby Bone and Tissue Bank has been successfully inaugurated by our Hon’ble Union Home Minister of India, Shri Amit Shah at our Krishna Shalby Hospital in Ahmedabad. Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people'slives. Deepak Anand, Global Chief Business Officer, said: During the third quarter of this financial year, our implant business made significant progress, generating revenues of Rs 269 million up by 25% YOY, with contributions from the USA and OUS at 33% and 67% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the South Asian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries. With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth with sustainable profitability, while also expanding and deepening our presence by opening up new geographies. These efforts will ultimately drive the creation of sustainable value for allstakeholders at Shalby. Result PDF
Conference Call with Shalby Ltd. Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Shalby announced Q2FY25 results Consolidated Revenue at Rs 2,747 million in Q2FY25. Consolidated EBITDA at Rs 398 million in Q2FY25. Consolidated PBT at Rs 137 million in Q2FY25. Occupied Bed during the quarter were 690. In patient count (incl. Day Care) of 23,907, growth of 5.5% YoY. ARPOB during the quarter was 38,779, growth of 7.3% YoY. Shanay Shah, President, Shalby, said: The company has shown a decent consolidated performance in Q2FY25 with a revenue of 275 crore with growth of 12.7% on YoY basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year. I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 5.5% rise in In-patient count (including day care) year-on-year in Q2FY25. Notably, ARPOB and ALOS stood at Rs 38,779 and 3.6 respectively in Q2FY25, compared to Rs 36,136 and 3.92 in the corresponding quarter of the previous year improved by 7.3% and 8.2% respectively. Our core specialties, including Arthroplasty, Onco-Science, Cardiac Science, Orthopaedic, Critical Care & General Medicine, and Neurology, collectively contributed 80% to the revenues in Q2FY25. On a standalone performance, our revenue has de-grown by 2.4% due to reduction in Surgeries by 7% on YoY basis. Rajasthan and Gujarat had witnessed a major rain fall in Q2FY25, where most districts in Gujarat and Rajasthan experienced heavy flooding which resulted in patients postponing elective surgeries. This resulted the major dip in surgeries in the Arthroplasty business as well as other specialities. Our EBIDTA on stand-alone performance has de-grown due to the above reason which has resulted in higher expenses in proportion to revenue. Our Homecare business contributed Rs 3.88 crore in Q2FY25 compared to Rs 3.64 crore in Q1FY24. Additionally, our Shalby Academy vertical witnessed an encouraging response, with over 1135 students enrolled in various healthcare programs during Q2FY25. Furthermore, our Realized Return on Capital Employed from the hospital business stood at 15% in Q2FY25 on an annualized basis. As of the quarter's close, our net debt balance at the group level amounted to Rs 2,047 million, with a net cash balance of Rs 742 million at the standalone level, reinforcing our ability to support strategic growth initiatives. Shalby has continued to achieve numerous milestones driven by clinical excellence and patient satisfaction, and we take pride in making a positive impact on people's lives. Deepak Anand, Global Chief Business Officer, Shalby, said: During the second quarter of this financial year, our implant business made significant progress, generating revenues of Rs 278 million up by 90% YOY, with contributionsfrom the USA and OUS at 30% and 70% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the Indonesian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries. With our key strategies firmly in place, our team is fully dedicated to executing these plans flawlessly. Shalby is well-positioned to achieve double-digit growth with sustainable profitability, while also expanding and deepening our presence by opening up new geographies. These efforts will ultimately drive the creation of sustainable value for allstakeholders at Shalby. Result PDF
Conference Call with Shalby Ltd. Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.